Video Series

Three medical experts highlight unmet needs they routinely run into while treating patients with NSCLC.

Joshua Sabari, MD, provides a breakdown of advanced non-small cell lung cancer (NSCLC) and its actionable mutations.

Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.

Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.

Dr Kristin Highland continues the treatment landscape discussion, focusing on systemic sclerosis ILD (SSc-ILD) and clinical trial data that studied therapy options for IPF, PF-ILD, and SSc-ILD.

The panel provides an overview of the treatment landscape for idiopathic pulmonary fibrosis (IPF) and progressing fibrosing ILD (PF-ILD).

Dr Arwen Podesta explains her PDT patient selection process and the factors she considers before treatment.

Dr Podesta calls on her experience using PDTs with patients to describe what successes and challenges are common.

Drs Noble and Highland explain the typical treatment goals physicians aim for when looking at ILD therapy options.

Ryan Haumschild, PharmD, MS, MBA, and Kristin Highland, MD, explain the clinical and economic burdens associated with ILD treatment.

Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.

Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.

Arwen Podesta, MD, provides an overview of how PDTs have evolved over the past 6 years since their introduction into the medical world.

Two experts define prescription digital therapeutics (PDTs) and their role in behavioral care therapy.

Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.

Joshua Richter, MD, and Jonathan L. Kaufman, MD, define and provide a basic understanding of relapsed/refractory multiple myeloma (RRMM).

Daniel Culver, DO, and Paul Noble, MD, highlight the types of physicians who manage patients with different forms of ILD, from diagnosis to treatment, as well as the process of referrals.

Daniel Culver, DO, and Paul Noble, MD, talk about incidence and prevalence typically seen with patients with ILD.

Panelists share their final insights on improving the trajectory for women’s health care.

This expert panel considers an increasing collaborative effort between payers, patients, and providers for patient-centered care.

A payer discusses medical exceptions processes and triggers for a class review for drugs in women’s health, along with wraparound programs for uterine fibroids and endometriosis.

A medical professional explains the many facets of the prior authorizations process for drugs in women’s health.

Ryan Haumschild, PharmD, MBA, MS, provides background on the Affordable Care Act (ACA) within the scope of women’s health, including specific mandates on contraceptives.

Dr Slipczuk concludes our discussion by detailing healthcare disparities commonly seen within ASCVD treatment.

A cardiology expert considers the future of lipid management within health systems and ways they can improve engagement from all parties.

Dr Slipczuk explores quality metrics, elaborating on ways to improve and align them with the latest cardiology treatment guidelines and payer considerations.

Key opinion leaders share their perspectives on utilization management strategies in treatment of women’s health.

The panel deliberates appropriate surgical intervention in women with uterine fibroids or endometriosis.

Dr Slipczuk offers strategies for sharing information and guiding appropriate ASCVD treatment both within and outside closed health systems.

Leandro N. Slipczuk, MD, PhD, details his organization’s effort to support uptake of PCSK9 inhibitors in the inpatient setting.